

ERRATUM

Open Access



Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group

George S. Laszlo¹, Todd A. Alonzo^{2,3}, Chelsea J. Gudgeon¹, Kimberly H. Harrington¹, Alex Kentsis^{4,5,6}, Robert B. Gerbing³, Yi-Cheng Wang³, Rhonda E. Ries¹, Susana C. Raimondi^{3,7}, Betsy A. Hirsch^{3,8}, Alan S. Gamis^{3,9}, Soheil Meshinchi^{1,3,10} and Roland B. Walter^{1,11,12*}

Erratum

The original article [1] contains an omission of information in the **Financial support** sub-section of the **Declarations** section.

The authors would like to acknowledge the Andrew McDonough B+ Foundation for financial support of co-author Dr Yi-Cheng Wang throughout this study, and regret this inadvertent omission from the original publication.

Author details

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA 98109-1024, USA. ²Department of Biostatistics, University of Southern California, Los Angeles, CA, USA. ³Children's Oncology Group, Monrovia, CA, USA. ⁴Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, NY, USA. ⁵Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ⁶Weill Medical College of Cornell University, New York, NY, USA. ⁷Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. ⁸Department of Laboratory Medicine and Pathology, University of Minnesota Cancer Center, Minneapolis, MN, USA. ⁹Division of Hematology-Oncology, Children's Mercy Hospitals and Clinics, Kansas City, MO, USA. ¹⁰Department of Pediatrics, University of Washington, Seattle, WA, USA. ¹¹Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. ¹²Department of Epidemiology, University of Washington, Seattle, WA, USA.

Received: 17 November 2016 Accepted: 28 November 2016

Published online: 30 November 2016

* Correspondence: rwalter@fredhutch.org

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA 98109-1024, USA

¹¹Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA

Full list of author information is available at the end of the article



© The Author(s). 2016 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Reference

1. Laszlo GS, et al. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. *J Hematol Oncol.* 2015;8:115. doi:10.1186/s13045-015-0215-4.